Edwards Lifesciences Upgraded On TAVR Market Revival
Edwards Lifesciences (EW) was up 4% early Tuesday after JPMorgan upgraded the stock to overweight from neutral, saying that its fundamentals are strong despite a recent market slowdown and increased competition from Medtronic (MDT). Analyst Michael Weinstein wrote in a research note that Edwards stock has fallen back from its March high on concerns of a slowdown in the transcatheter aortic valve replacement (TAVR) market. Last year the market grew